menu
    • menu
    [{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tesaro \/ Undisclosed"},{"orgOrder":0,"company":"Tesaro","sponsor":"Costantine Albany","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rolapitant HCl","moa":"Neurokinin 1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Tesaro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tesaro \/ Costantine Albany","highestDevelopmentStatusID":"8","companyTruncated":"Tesaro \/ Costantine Albany"}]

    Find Clinical Drug Pipeline Developments & Deals for Rolapitant

    Menu

    Rolapitant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Costantine Albany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms, Germ Cell and Embryonal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2019

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Costantine Albany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the ...

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 05, 2015

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolap...

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 09, 2015

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 07, 2014

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Ch...

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2011

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Che...

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2011

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Tesaro

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Che...

                            Details : Rolapitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 26, 2011

                            Lead Product(s) : Rolapitant HCl

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth